C-Encode Logo

FRAX, tabular · Westview Imaging Centre, MRN SMP-100234, DOB 1949-01-01

Bone Mineral Density

DIAGNOSTIC CATEGORY:
OSTEOPOROSIS.
10-YEAR FRAX:
Major Osteoporotic Fracture: 11.3 %
Hip Fracture: 2.6 %
The FRAX score reflects the theoretical risk of a treatment-naive patient. This model does not account for the benefits of pharmacotherapy and may therefore overestimate the risk in a patient on bone-active drug therapy.
RISK FACTORS:
None.
Bone-active drug therapy:
No.
BONE MINERAL DENSITY DATA:
Compared with: 2024-12-30
DENSITY
(g/cm²)
T-SCORE
Z-SCORE
DENSITY
PRIOR
(g/cm²)
CHANGE
(g/cm²)
CHANGE
(%)
Spine L1-L4.1.085-0.90.71.104-0.019-1.7
Left Femoral Neck.0.687-2.5-1.1
Left Total Hip.0.804-1.6-0.40.807-0.003-0.4
PRECISION: Spine 0.3 %
Left Hip 0.2 %
CLINIC:Westview Imaging Centre
LSC: Spine: 0.035 gm/cm2; Total hip: 0.027 gm/cm2
WEIGHT
Current
60.6  kg
Previous
61.8  kg
Change
1.2  kg
Change(%)
1.9  %
HEIGHT
Current
162.0  cm
Previous
162.5  cm
Change
-0.5  cm
LIMITATIONS: N/A.
INTERPRETATION:
Spine: No significant interval change.
Left Hip: No significant interval change.
Bone-active drug therapy is suggested [Osteoporosis Canada]. Evaluation for secondary causes of reduced bone density is warranted if not already performed.
NEXT ELIGIBLE OHIP FOLLOW-UP: 1 year, if medically necessary. No earlier than: 2027-08-25

Sample output for illustration. Patient details are fictional; the report layout and wording are produced by DXA Encode.